Robert Taylor Nelsen

Mr, Robert Taylor NELSEN, was appointed as a Director on June 22, 2018, and re-designated as a non-executive Director on March 24, 2021. Since November 2018, February 2019, and February 2019, he has been serving as a director of Brii HK, Brii Shanghai, and Brii Beijing, respectively.

Since 1994, Mr. Nelsen has been serving as a co-founder and managing director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies, and he has played a significant role in the early sourcing, financing, and development of more than 30 biopharmaceutical companies. In addition, Mr. Nelsen currently holds directorships in multiple biopharmaceutical companies listed on the NASDAQ stock exchange or the Stock Exchange. As a board member, Mr. Nelsen would generally attend board meetings to provide guidance to company strategy and discuss pertinent issues such as fundraising, recruiting, R&D, and the status of clinical programs. Mr. Nelsen also previously served as a trustee of Fred Hutchinson Cancer Research Center.

Mr. Nelsen obtained his Bachelor of Science with majors in Economics and Biology from the University of Puget Sound in the United States in June 1985 and a Master of Business Administration from the University of Chicago in the United States in June 1987.